3Van der Voort OH, Gerritsen RT, Kuiper MA, et al. Filter run time in CWH:pre-versus postdilution and nadroparin versus regional heparinprotamine anticoagulation[J]. Blood, Purif, 2005, 23:175- 180.
4Stamatiadis DN, Helioti H, Mansour M,et al. Hemodialysis for patients bleeding or a risk for bleeding, can be simple, safe and efficient [J]. Clin Nephrol, 2004,62 ( 1 ) : 29-34.
5Hetzel GR, Sucker C. The heparin: all a nephrologist should know[J]. Nephrol Dial Transplant, 2005, 20:2036- 2042.
6Bihorac A, Ross EA. Continuous venovenous hemofiltration with citrate-based replacement fluid: effiCacy, safety, and impact on nutrition[J]. Am J Kidney Dis, 2005,46 (5) : 908- 918.
7Ridel C, Uereada L, Bene B, et al. Regional citrateanticoagulation during hemodialysis: a simplified proeedureusing Duocart biofiltration[J]. Blood Purif, 2005,23(6) : 473-480.
8Weijmer MC, et al. Randomized, clinical trial comparison of trisodium citrate 30% and heparin as catheter-locking solution in hemodialysis patients[J]. J Am Soc Nephrol, 2005,16 (9) : 2769-2777.
9Hetzet GR, Taskaya G,Sucker C, et al. Citrate plasma levels in patients under regional anticoagulation in continuous venovenous hemofiltration [J]. Am J Kidney Dis, 2006,48 (5): 806- 811.
10Murray PT, Reddy BV,Grossman EJ,et al. A prospective com parison of three argatroban treatment regimens during hemodialy sis in endstage renal disease[J]. Kidney Int,2004, 66(6):2446.
